 |
|
|
| |
Long-acting cabotegravir (CAB) plus rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 week 48 outcomes
|
| |
| |
AIDS 2024 July 20-26 Munich
Aditya Gaur
|
| |
|
|
|
|
|
